Telemus Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $1.29M | Sell |
25,110
-547
| -2% | -$28.7K | 0.11% | 137 |
|
|
2023
Q3 | $1.49M | Sell |
25,657
-1,448
| -5% | -$88.7K | 0.14% | 123 |
|
|
2023
Q2 | $1.73M | Buy |
27,105
+909
| +3% | +$61K | 0.15% | 124 |
|
|
2023
Q1 | $1.82M | Buy |
26,196
+830
| +3% | +$58.5K | 0.16% | 127 |
|
|
2022
Q4 | $1.85M | Sell |
25,366
-479
| -2% | -$36.1K | 0.17% | 116 |
|
|
2022
Q3 | $1.84M | Buy |
25,845
+342
| +1% | +$24.8K | 0.19% | 111 |
|
|
2022
Q2 | $1.96M | Sell |
25,503
-2,347
| -8% | -$179K | 0.19% | 110 |
|
|
2022
Q1 | $2.03M | Buy |
27,850
+120
| +0.4% | +$8.06K | 0.18% | 112 |
|
|
2021
Q4 | $1.73M | Sell |
27,730
-559
| -2% | -$32.8K | 0.14% | 134 |
|
|
2021
Q3 | $1.67M | Sell |
28,289
-7,586
| -21% | -$500K | 0.14% | 132 |
|
|
2021
Q2 | $2.4M | Sell |
35,875
-1,846
| -5% | -$120K | 0.17% | 103 |
|
|
2021
Q1 | $2.38M | Buy |
37,721
+7,722
| +26% | +$480K | 0.16% | 110 |
|
|
2020
Q4 | $1.86M | Buy |
29,999
+1,939
| +7% | +$119K | 0.14% | 129 |
|
|
2020
Q3 | $1.72M | Buy |
28,060
+6,388
| +29% | +$384K | 0.13% | 139 |
|
|
2020
Q2 | $1.25M | Sell |
21,672
-75
| -0.3% | -$4.49K | 0.1% | 159 |
|
|
2020
Q1 | $1.3M | Sell |
21,747
-7,472
| -26% | -$457K | 0.11% | 148 |
|
|
2019
Q4 | $1.88M | Buy |
29,219
+8,484
| +41% | +$486K | 0.14% | 121 |
|
|
2019
Q3 | $1.05M | Buy |
20,735
+300
| +1% | +$14.1K | 0.08% | 171 |
|
|
2019
Q2 | $927K | Sell |
20,435
-1,066
| -5% | -$49.7K | 0.08% | 171 |
|
|
2019
Q1 | $1.03M | Sell |
21,501
-507
| -2% | -$25.3K | 0.08% | 189 |
|
|
2018
Q4 | $1.14M | Sell |
22,008
-1,650
| -7% | -$88.7K | 0.09% | 164 |
|
|
2018
Q3 | $1.47M | Sell |
23,658
-396
| -2% | -$23.5K | 0.11% | 148 |
|
|
2018
Q2 | $1.33M | Buy |
24,054
+139
| +0.6% | +$7.51K | 0.1% | 165 |
|
|
2018
Q1 | $1.51M | Sell |
23,915
-255
| -1% | -$16.4K | 0.12% | 150 |
|
|
2017
Q4 | $1.48M | Buy |
24,170
+19,129
| +379% | +$1.2M | 0.11% | 156 |
|
|
2017
Q3 | $321K | Sell |
5,041
-7,489
| -60% | -$437K | 0.04% | 263 |
|
|
2017
Q2 | $698K | Buy |
12,530
+1,155
| +10% | +$62.9K | 0.07% | 189 |
|
|
2017
Q1 | $619K | Buy |
11,375
+3,519
| +45% | +$193K | 0.06% | 194 |
|
|
2016
Q4 | $459K | Sell |
7,856
-3,392
| -30% | -$185K | 0.06% | 204 |
|
|
2016
Q3 | $606K | Sell |
11,248
-614
| -5% | -$39.4K | 0.07% | 198 |
|
|
2016
Q2 | $872K | Buy |
11,862
+2,392
| +25% | +$169K | 0.11% | 159 |
|
|
2016
Q1 | $605K | Buy |
9,470
+3,965
| +72% | +$250K | 0.1% | 168 |
|
|
2015
Q4 | $379K | Buy |
+5,505
| New | +$364K | 0.1% | 102 |
|
|
2015
Q1 | – | Sell |
-4,168
| Closed | -$246K | – | 135 |
|
|
2014
Q4 | $246K | Hold |
4,168
| – | – | 0.06% | 120 |
|
|
2014
Q3 | $213K | Sell |
4,168
-211
| -5% | -$10.5K | 0.06% | 121 |
|
|
2014
Q2 | $212K | Hold |
4,379
| – | – | 0.06% | 123 |
|
|
2014
Q1 | $227K | Hold |
4,379
| – | – | 0.06% | 117 |
|
|
2013
Q4 | $233K | Sell |
4,379
-244
| -5% | -$12.4K | 0.07% | 109 |
|
|
2013
Q3 | $214K | Buy |
+4,623
| New | +$203K | 0.06% | 143 |
|
Other funds holding BMY
Telemus Capital's BMY Position: Q4 2023 in Review
Telemus Capital reduced its Bristol-Myers Squibb (BMY) stake by 2.1% in Q4 2023, selling an estimated $28.7K and leaving 25,110 shares worth $1.29M. The position accounts for 0.11% of the portfolio, ranked #137.
Telemus Capital first reported a position in BMY in Q3 2013 and has held it in 39 quarters since. The position peaked at $2.4M in Q2 2021. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.
- Telemus Capital held 25,110 shares of Bristol-Myers Squibb worth $1.29M as of Q4 2023.
- Telemus Capital sold 547 Bristol-Myers Squibb shares in Q4 2023, an estimated $28.7K.
- Bristol-Myers Squibb made up 0.11% of Telemus Capital's portfolio in Q4 2023, its #137 holding.
- Telemus Capital first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 39 quarters since.
- Telemus Capital's Bristol-Myers Squibb position peaked at $2.4M in Q2 2021.
- 2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.
Based on Telemus Capital's 13F filing for Q4 2023, filed 1 Feb 2024.